Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.
作者： Daniela Furrer , François Sanschagrin , Simon Jacob , Caroline Diorio
关键词:
摘要: … Another important aspect is that fluorescence signal counting is time consuming. To overcome this problem, image analysis software for the automated evaluation of fluorescent signals …
oup.com
oxfordjournals.org
ascpjournals.org参考文章(161)
Laura Zorzino, Marco Colleoni, Maria Teresa Sandri, Laura Orlando, Rita Passerini, Giuseppe Viale, Harriet Johansson, Serum Levels of HER2 ECD Can Determine the Response Rate to Low Dose Oral Cyclophosphamide and Methotrexate in Patients with Advanced Stage Breast Carcinoma Anticancer Research. ,vol. 24, pp. 1261- 1266 ,(2004)
D. Wallwiener, R. Kurek, K. Sotlar, U. Vogel, S. E. Clare, B. Aydeniz, H. Neubauer, K. Tabiti, R. Speer, V. Henkel, Peter Benöhr, A. Reiser, Her-2/neu expression in breast cancer--A comparison of different diagnostic methods. Anticancer Research. ,vol. 25, pp. 1895- 1900 ,(2005)
Rohit Bhargava, Priti Lal, Beiyun Chen, Chromogenic In Situ Hybridization for the Detection of HER-2/neu Gene Amplification in Breast Cancer With an Emphasis on Tumors With Borderline and Low-Level Amplification Does It Measure Up to Fluorescence In Situ Hybridization? American Journal of Clinical Pathology. ,vol. 123, pp. 237- 243 ,(2005) , 10.1309/C4PEBGB9LN830TVL
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
Andreea Nistor, Peter H Watson, Norman Pettigrew, Karim Tabiti, Angelika Dawson, Yvonne Myal, Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer BMC Clinical Pathology. ,vol. 6, pp. 2- 2 ,(2006) , 10.1186/1472-6890-6-2
Michael T. Deavers, Emily Tarco, Lavinia P. Middleton, Nour Sneige, Pamela Puig, Kaye Barr, Lori J. Heydon, Kathy M. Price, Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Archives of Pathology & Laboratory Medicine. ,vol. 133, pp. 775- 780 ,(2009) , 10.1043/1543-2165-133.5.775
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
David G. Hicks, Raymond R. Tubbs, Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human Pathology. ,vol. 36, pp. 250- 261 ,(2005) , 10.1016/J.HUMPATH.2004.11.010
Isabelle Soerjomataram, Marieke W. J. Louwman, Jacques G. Ribot, Jan A. Roukema, Jan Willem W. Coebergh, An overview of prognostic factors for long-term survivors of breast cancer Breast Cancer Research and Treatment. ,vol. 107, pp. 309- 330 ,(2008) , 10.1007/S10549-007-9556-1
Glenn D. Francis, Mark A. Jones, Geoffrey F. Beadle, Sandra R. Stein, Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagnostic Molecular Pathology. ,vol. 18, pp. 88- 95 ,(2009) , 10.1097/PDM.0B013E31816F6374